Bi-stable bifurcated stent petal geometry

Information

  • Patent Grant
  • 8277501
  • Patent Number
    8,277,501
  • Date Filed
    Friday, December 21, 2007
    16 years ago
  • Date Issued
    Tuesday, October 2, 2012
    11 years ago
Abstract
A stent has a substantially cylindrical tubular body with at least one expandable side branch that has a plurality of members. The plurality of members includes at least one first member having a first width and at least one second member having a second width, where the first width is greater than the second width. Each of the at least one first members and each of the at least one second members define a cell that has at least two stable cell geometries.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

Not Applicable


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Not Applicable


BACKGROUND OF THE INVENTION

A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.


Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).


Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.


Within the vasculature, it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.


The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.


All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.


Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.


BRIEF SUMMARY OF THE INVENTION

In at least one embodiment, the invention is directed to a stent with a side branch comprising a plurality of members defining at least one cell having at least two stable cell geometries, a “bi-stable” cell. In some embodiments, some of the plurality of members of the stent form a double bi-stable cell geometry. In other embodiments, at least one of the members defining the bi-stable cell has at least one hinge. In some embodiments, the side branch has a plurality of cells having at least two stable cell geometries arranged in a column.


These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for further understanding of the invention, its advantages and objectives obtained by its use, reference can be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described an embodiments of the invention.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

A detailed description of the invention is hereafter described with specific reference being made to the drawings.



FIG. 1A is view of a configuration of a cell that has a bi-stable geometry, with the cell in a first stable state.



FIG. 1B is a view of the cell in FIG. 1A in a second stable state.



FIG. 2A is a view of another configuration of a cell that has a bi-stable geometry, with the cell in a first stable state.



FIG. 2B is a view of the cell in FIG. 2A in a second stable state.



FIG. 3A is a view of a configuration of a cell with at least one hinge that has at least two stable states/cell geometries, with the cell in a first stable state.



FIG. 3B is a view of the cell in FIG. 3A in a second stable state.



FIG. 4A is a view of a configuration of a cell that has a bi-stable geometry with two connectors, with the cell in a first state.



FIG. 4B is a view of the cell in FIG. 4A in a second stable state.



FIG. 5 is a view of a configuration of a cell that has double bi-stable geometry and off center connectors to open the cell, with the cells in the first state.



FIG. 6 is a view of a configuration of a cell that has double bi-stable geometry, with the cells in the first state.



FIG. 7A is a view of a configuration of a cell that has a bi-stable geometry with built in hinge points, with the cell in a first stable state.



FIG. 7B is a view of the cell in FIG. 7A in a second stable state.



FIG. 8A is a view of a column of bi-stable cells that have at least two stable states/cell geometries engaged to one another, with the bi-stable cells in a first stable state.



FIG. 8B is one of the bi-stable cells in FIG. 8A in an intermediate state.



FIG. 8C is one of the bi-stable cells in FIG. 8A in an alternative intermediate state.



FIG. 8D is a view of the column of cells in FIG. 8A in a second stable state.



FIG. 8E is a view of a column of a plurality of cells in where adjacent cells are offset from one another.



FIG. 9A is a view of a configuration of cells that have at least two stable states/cell geometries, with the cells in a first stable state, where two adjacent cells are partially defined by a common cell segment.



FIG. 9B is a view of the cells in FIG. 9B in a second stable state.



FIG. 10A is a flat view of a side branch configuration with a plurality of cells with at least two stable states/cell geometries, with the cells in a first stable state.



FIG. 10B is an enlarged view of a portion of the side branch in FIG. 10A.



FIG. 10C is a view of the cell in FIG. 10B engaged to a portion of the side branch in an alternative manner.



FIG. 11A is a flat view of another side branch configuration with a plurality of cells with at least two stable states/cell geometries, with the cells in a first stable state.



FIG. 11B is an enlarged view of a portion of the side branch in FIG. 11A.



FIG. 12 is a perspective view of a portion of a stent with the side branch of FIG. 11A in an unexpanded state, and the bi-stable cells in a first state.



FIG. 13 a perspective view of the stent portion of FIG. 12 with the side branch in a partially expanded state.



FIG. 14 is a perspective view of the stent portion of FIG. 13 with the side branch a further partially expanded state.



FIG. 15A is a perspective view of the stent portion of FIG. 14 with the side branch in an expanded state, and the bi-stable cells in a second state.



FIG. 15B is a side view of the stent portion of FIG. 14 with the side branch in an expanded state.



FIG. 15C is an end view of the stent portion of FIG. 14 with the side branch in an expanded state.



FIG. 16A is an alternative configuration for a petal in a side branch having a cell with at least two stable states/cell geometries, with the cell in a first stable state.



FIG. 16B is the petal of FIG. 16B, with the cell in a second stable state.



FIG. 16C is a petal with two cells with at least two stable states.



FIG. 17 is a flat view of a side branch configuration having a plurality of the cells with at least two stable states/cell geometries arranged in columns.



FIG. 18 is a flat view of a side branch configuration having a ring of cells with at least two stable states/cell geometries.





DETAILED DESCRIPTION OF THE INVENTION

While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.


For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.


As used herein the term ‘stent’ refers to an expandable prosthesis for implantation into a body lumen or vessel and includes devices such as stents, grafts, stent-grafts, vena cava filters, expandable frameworks, etc.


As used herein, the term ‘bi-stable cell’ refers to a cell that has two or more discrete stable configurations, geometries and/or states 36,38. Thus, bi-stable cells includes cells that are multi-stable, i.e. cells with more than two discrete stable configurations.


Referring now to the drawings which are for the purposes of illustrating embodiments of the invention only and not for purposes of limiting same, FIGS. 1-9 show examples of bi-stable cells 48 with different configurations, geometries and/or states. In at least one embodiment, the bi-stable cell 48 has a first stable configuration 36, with a first distance between the first and second cell segments 32, 34 and a first area (A1) defined by the cell segments 32, 34 and a second stable configuration 38 with a second larger distance between the first and second cell segments 32, 34 and second larger area (A2) defined by the cell segments 32, 34.


When a force is applied to the bi-stable cell 48, the bi-stable cell 48 will tend to, or exert a force in the direction of, one of the discrete configurations. In at least one embodiment, the bi-stable cell 48 will tend to one or another of the first and second configurations 36, 38 depending on whether the bi-stable cell 48 has been compressed beyond a transition point. If the bi-stable cell 48 has been compressed beyond the transition point, the bi-stable cell 48 will tend toward a closed configuration, or first state 36. Conversely, if the bi-stable cell 48 has not been compressed to the transition point, the bi-stable cell 48 will tend towards an open configuration or second state 38. As expansive forces are applied to the side branch 20 of the stent 10, the first cell segment 32 and the second cell segments 34 will move away from one another so that the bi-stable cell 48 widens and expands, thereby increasing the area of the bi-stable cell 48.


Thus, the bi-stable cell 48 has an equilibrium position between two stable states, e.g. the first and second states 36, 38. When the force applied to the bi-stable cell 48 exceeds the equilibrium position, the bi-stable cell 48 snaps into one of its stable states depending upon the original state of the bi-stable cell 48 and the direction of the force. Note, that in a bi-stable cell 48, all positions between the stable states, e.g. the first and second states 36, 38, are unstable and can only be maintained by an external force. In a bi-stable cell 48 with more than two stable states, there is an equilibrium position between each stable state. For example, in a bi-stable cell 48 with a first state 36, an intermediate state 37 and a second state 38 there is an equilibrium position between the first state 36 and the intermediate state 37 and an equilibrium position between the intermediate state 37 and the second state 38. Bi-stable cells are also discussed in commonly assigned application Ser. No. 11/368,913, entitled Non-Foreshortening Sheaths and Assemblies for Use, hereby incorporated by reference in its entirety.


As shown, for example in FIGS. 1A and 1B, the bi-stable cell 48 is defined by at least one first cell segment 32 and at least one second cell segment 34 which are constructed and arranged so that the second cell segment 34 is more flexible, weaker, or less rigid, than the first cell segment 32, so that the second cell segment 34 can assume different stable positions and provide the bi-stable cell 48 with at least two stable states. In at least one embodiment, the first cell segment 32 has a greater width (W1) than the second cell segment 34 (W2) as shown in FIGS. 1B and 2B. As used in this application, the width of a member, e.g. the first cell segment 32, is measured along the outer surface of the stent. In some embodiments, the first cell segment 32 is more rigid than the second cell segment 34. In other embodiments, the first cell segment 32 is stronger than the second cell segment 34. The strength and rigidity of the cell segments 32, 34 can be changed by using different materials for the second cell segment 34 than for the first cell segment 32 or by treating one cell segment 32, 34 differently than the other cell segment 32, 34. For example, some materials can be strengthened by heat treatment. Thus, in this embodiment, the first cell segment 32 would be heat treated so that it would be stronger than the second cell segment 34. Some materials, such as Nitinol, for example, become more pliable or less rigid when heated. Thus, if the cell segments 32, 34 are made from Nitinol, the second cell segment 34 would be heat treated so that it would be less rigid than the first cell segment 32.


Note that the first and second cell segments 32, 34 can have any length. The length and/or the configuration of the first and second cell segments 32, 34 affects the area of the bi-stable cell 48 in both the first and second states 36, 38. The bi-stable cell 48 has a first area (A1) in the first state 36, a second area (A2) in the second state 38 and the first area (A1) is smaller than the second area (A2).


Each cell segment 32, 34 has a length. If the cell segment 32, 34 is not straight, the length is the pathway from one end of the cell segment 32, 34 to the second end of the cell segment 32, 34. As shown in FIGS. 1A and 1B, the length of the first cell segment 32 is the same as the length of the second cell segment 34. In some embodiments, the length of the first cell segment 32 is different than the length of the second cell segment 34, as shown for example in FIGS. 9A and 9B.


In some embodiments, the first and second cell segments 32, 34 have the same configuration in the first state 36 and in the second state 38, as shown, for example, in FIGS. 1A and 1B. In this embodiment, the first and second cell segments have a curvilinear configuration. As shown in FIG. 1A, the first and second cell segments 32, 34 have the same configuration and the same orientation relative to the longitudinal axis of the stent in the first state 36. Thus, the first cell segment 32 and the second cell segment 34 can be described as having complementary shapes in the first state 36. Alternatively, the first and second cell segments 32, 34 can be described as being parallel to one another in the first state 36. In FIG. 1B, the first and second cell segments 32, 34 have the same configuration, but opposite orientations relative to the longitudinal axis of the stent in the second state 38.


In other embodiments, the first and second cell segments 32, 34 have the same configuration in the first state 36 and different configurations in the second state 38, as shown, for example, in FIGS. 3A and 3B. In this embodiment, the first cell segment 32 has the same configuration in the first and second states 36, 38 and the second cell segment 32 has a first configuration in the first state 36 and a second configuration in the second state 38, where the first and second configurations are different. In FIGS. 3A and 3B, the first and second cell segments 32, 34 have the same curvilinear configuration in the first state 36 and different curvilinear configurations in the second state 38.


In some embodiments, the first and second cell segments 32, 34 have different configurations in both the first and second states 36, 38. For example, as shown in FIGS. 7A and 7B, the first and second cell segments 32, 34 have different configurations in the first state 36 and the second state 38. In at least one embodiment, the first cell segment 32 has the same configuration in both the first state 36 and in the second state 38. As shown in FIG. 7A, portions of the first cell segment 32 and portions of the second cell segment 34 are complementary to one another in the first state 36, as shown by hatch marks. Thus, in this embodiment, unlike FIG. 1A, only a portion of the first and second cell segments 32, 34 are complementary to one another in the first state 36 instead of the entire first and second cell segments 32, 34 being complementary.


The shape of the first and second cell segments 32, 34 and the relationship of the first and second cell segments 32, 34 to one another determines the configuration or cell geometry of the bi-stable cell 48. As shown in the figures, the cell geometry of the bi-stable cell 48 is different in the first and second states 36, 38. Thus, the bi-stable cell 48 has a first stable cell geometry in the first state 36 and a second stable cell geometry in the second state 38 and the first and second stable cell geometries are different from one another.


For example, in FIGS. 1A and 1B, the first stable cell geometry of the bi-stable cell 48 is a curvilinear configuration and the second stable cell geometry of the bi-stable cell 48 is an oval shaped or eye shaped configuration. Similarly, in FIGS. 2A and 2B, the first stable cell geometry of the bi-stable cell 48 is an angular C shaped configuration and the second stable cell geometry of the bi-stable cell 48 is a polygonal or hexagonal shaped configuration. The first stable cell geometry in FIG. 2A can also be described as a boat shaped configuration.


Other examples of different stable cell geometries in the first and second states 36, 38 are shown in FIGS. 3A-B, 4A-B and 7A-B. In the bi-stable cell 48 embodiments of FIGS. 3-4, the first stable cell geometry of the bi-stable cell 48 is a curvilinear configuration and the second stable cell geometry of the bi-stable cell 48 is a symmetrical configuration. Note that the symmetrical configurations or cell geometries in FIG. 3B and 4B are different due to the different configurations of the second cell segment 34 in the second state 38. The cell geometry of FIG. 3B is cape shaped whereas the cell geometry of FIG. 4B is hat shaped. The bi-stable cell 48 embodiment in FIG. 7 has a first stable cell geometry in the form of a “wing” configuration and a second stable cell geometry that is triangular shaped.


In at least one embodiment, shown for example, in FIGS. 3A, 3B, 7A-B, 8A-C, the second cell segment 34 and/or the first cell segment 32 has at least one hinge 40. It is within the scope of the invention for either or both of the first and second cell segments 32, 34 to have one, two, three, four, five, six or more hinges 40 along the length of the cell segment 32, 34. In at least one embodiment, the hinges 40 are deformable. In some embodiments, the hinges 40 are elastically deformable. In other embodiments, the hinges 40 are plastically deformable. In some embodiments, the hinges 40 are regions in the cell segment 32, 34 that have a smaller width than the adjacent regions of the cell segment 32, 34.


In at least one embodiment, a bi-stable cell 48 defined by at least one cell segment 32, 34 having hinges 40 has more than two stable states, 36, 37, 38. For example, the bi-stable cell 48 shown in FIG. 8A-D has two different intermediate stable states 37a,b. The second cell segment 34 can be described as having a proximal section, a middle section and a distal section. In the intermediate stable state 37a,b embodiments, one of the proximal section or the distal section stays in the first stable state 36 position while the other is in the second stable state 38 position, with the middle section extending between the proximal and distal sections at an oblique angle. An oblique angle, as used in this application is any angle between 0 and 90 degrees and 90 and 180 degrees and a perpendicular angle is a 90 degree angle.


Thus, in this embodiment, the bi-stable cell 48 has more than two stable cell geometries. The bi-stable cell 48 has a first state 36 cell geometry, two different intermediate state cell geometry embodiments 37a,b and a second state cell geometry 38. Similar to FIG. 2A, the bi-stable cell 48 in FIG. 8A has first state cell geometry that is an angular C-shaped configuration. Note that the lengths of the proximal and distal sections of the second cell segment 34 and their angle to the middle section in FIGS. 2 and 8 are different, which results in angular C-shaped configurations or boat shaped configurations that are different from one another. As shown in FIGS. 8B-C, the bi-stable cell 48 has cell geometry that is an irregular configuration in both of the intermediate states 37a,b. The bi-stable cell 48 in FIG. 8D has the same cell geometry in the second state 38 as the bi-stable cell 48 in FIG. 2B, namely a hexagonal or polygonal configuration.


In at least one embodiment, members of the stent 10 are arranged to form a double bi-stable cell, as shown, for example, in FIGS. 5 and 6. A double bi-stable cell geometry comprises one first cell segment 32 and two second cell segments 34a,b arranged so that the first cell segment 32 is positioned between the two second cell segments 34a,b. Note that as with the bi-stable geometry, the first cell segment 32 is wider than both of the second cell segments 34a,b. The first cell segment 32 and second cell segment 34a define a first cell 48a and the first cell segment and second cell segment 34b define a second cell 48b. As shown in FIGS. 5 and 6, the first cell segment 32 and the second cell segments 34a,b have an S-shaped configuration. The configurations of the first and second cell segments 32, 34 in FIGS. 5 and 6 can also be described as curvilinear or sinusoidal.


In some embodiments, the first cell 48a and the second cell 48b have the same configuration in both the first state 36 and the second state 38. In other embodiments, the first cell 48a and the second cell 48b have the same configuration in the first state 36 and different configurations in the second state 38. One example of this embodiment, is if the first cell 48a has a configuration like FIG. 1 and the second cell 48b has a configuration like FIG. 3. Both cells in FIG. 1A and 3A have the same configuration in the first state 36 but different configurations in the second state 38.


In at least one embodiment, a connector 44 is engaged to the first cell segment 32 and/or the second cell segment 34. In at least one embodiment, the connectors 44 aid in the transition of the bi-stable cell from the first state 36 to the second state 38. In some embodiments, the connectors 44 open the bi-stable geometry by a twisting motion. In other embodiments, the connectors 44 open the bi-stable geometry due to the tension the connectors 44 exert on the second cell segment 34. In some embodiments, both second cell segments 34a,b of a double bi-stable cell transition to the second state 38. In other embodiments, only one of the second cell segments of a double bi-stable cell transitions to the second state 38.


In FIGS. 5 and 6 a connector 44 is engaged to both second cell segments 34a,b, although the connectors 44 are engaged to different positions along the lengths of the second cell segments 34a,b. In FIG. 5, the connectors 44 are engaged to a middle region of the second cell segments 34a,b. Similarly, the connectors 44 in FIGS. 4A and 4B are engaged to the middle region of the first and second cell segments 32, 34. In FIGS. 4 and 5, the connectors 44 are positioned on the same axis. In FIG. 4, the connectors 44 are perpendicular to the first and second cell segments 32, 34 while in FIG. 5, the connectors 44 are at an oblique angle to the first and second cell segments 32, 34. In FIG. 6, the connectors 44 are engaged toward the end regions of the second cell segments 34a,b. As shown in FIG. 6, the two connectors 44 are parallel to one another but it is within the scope of the invention for the connectors 44 to be at oblique angles to one another.


In some embodiments, bi-stable cells 48 are engaged to one another to form of columns 50 of bi-stable cells 48, as shown, for example, in FIGS. 8A-9B. The configurations of the bi-stable cells 48 forming the column 50 of bi-stable cells 48 in FIGS. 8A-9B are merely examples of possible configurations. It is within the scope of the invention for the bi-stable cells 48 forming a column 50 of bi-stable cells 48 to have any configuration. In some embodiments, the bi-stable cells 48 in the column 50 of bi-stable cells 48 have the same configuration. In other embodiments, at least one of the bi-stable cells 48 in a column 50 of bi-stable cells 48 has a different configuration than the other bi-stable cells 48. In some embodiments, the bi-stable cells 48 are aligned with one another as shown, for example, in FIG. 8D. In other embodiments, the bi-stable cells 48 are offset from one another, as shown, for example, in FIG. 8E.


In some embodiments, adjacent bi-stable cells 48 are directly engaged, as shown in FIGS. 8D and 9B, so that the second cell segment 34 of a first bi-stable cell 48a is engaged to the first cell segment 32 of a second bi-stable cell 48b. As shown in FIG. 8D, the entire length of the first and second cell segments 32, 34 are engaged to one another. However, it is within the scope of the invention for portions of the first and second cell segments 32, 34 to be engaged to one another. In FIGS. 9A and 9B, the first bi-stable cell 48a is engaged to the second bi-stable cell 48b by two second cell segments 34a. In this embodiment, the bi-stable cell 48a is defined by first cell segment 32a, two second cell segments 34a and first cell segment 32b.


In other embodiments, adjacent bi-stable cells 48 in a column 50 of bi-stable cells 48 are engaged by a connector 44, for example as shown in FIGS. 8E and 17. In at least one embodiment, the size/area of the bi-stable cells 48 in a column 50 of bi-stable cells 48 is the same. In at least one embodiment, the bi-stable cells 48 in a column 50 of bi-stable cells 48 have different sizes/area. Thus, the size/area of the bi-stable cells 48 in a column 50 of bi-stable cells 48 can sequentially decrease as shown, for example, in the side branch 20 of FIG. 17, to form a tapered column 50 of bi-stable cells 48.


Because any suitable stent geometry may be used for the tubular body of the stent 10, many figures only show the side branch 20 of the stent 10 without any structure, or only a small portion of structure, shown for the rest of the tubular body of the stent 10. It is understood that any suitable structure may be employed for the tubular body of the stent 10 including, but not limited to, the cellular patterns, shown by way of example only, in FIG. 12, U.S. Pat. Nos. 6,835,203, 6,348,065, and 6,013,091. Although, the bi-stable cell embodiments described in FIGS. 1-9 are discussed in reference to a side branch of a stent, it is within the scope of the invention for the bi-stable cell embodiments described herein to be used in the stent geometry of the tubular body of the stent. The tubular body of the stent can comprise only bi-stable cells or can comprise both bi-stable cells and cells that are not bi-stable cells, i.e. cells that have only one stable state, for example, cells 49 in FIG. 17.


One skilled in the art will recognize that the bi-stable cell geometries shown in FIGS. 1-9B can be incorporated into a side branch 20 in many different ways, some examples of which are provided hereinafter. FIG. 10A is a flat view of a non-limiting example of a configuration for a side branch 20 that has a plurality of bi-stable cells 48a and a plurality of cells 49 with one stable state. FIG. 10B is an enlarged view of a portion of the side branch 20 of FIG. 10A. Note that although the bi-stable cell 48 configuration shown in FIGS. 1A and 1B In the side branch 20 configuration shown in FIGS. 10A-C and 11A-B, the bi-stable cell 48 has the configuration shown in FIGS. 1A and 1B, but, as discussed above, it is within the scope of the invention for the bi-stable cell 48a to have any configuration.


It is also within the scope of the invention for the side branch 20 to have bi-stable cells 48 which define different areas in the first state 36 and/or different area in the second state 38. For example, the side branch 20 in FIG. 11A has a plurality of bi-stable cells 48a with a first area (A1) and a plurality of bi-stable cells 48b with a second area (A2), where the first area (A1) is larger than the second area (A2). In some embodiments, the first area (A1) is greater than the second area (A2) in both the first and second states 36, 38. As shown in FIGS. 11A and 11B, the lengths of the first and second cell segments 32, 34 of the bi-stable cells 48a with the first area (A1) are greater than the lengths of the first and second cell segments 32, 34 of the bi-stable cells 48b with the second area (A2).


The side branch 20 in FIG. 10A has twelve bi-stable cells 48, while the side branch 20 in FIG. 11A has twenty-four bi-stable cells 48. A side branch 20 can have any number of bi-stable cells 48, thus, it is within the scope of the invention for a side branch 20 to have one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty or more bi-stable cells 48.


As shown in FIG. 10A, the side branch 20 comprises a perimeter member 22 which has a circular shaped configuration. It is within the scope of the invention for the perimeter member 22 to have any configuration, including but not limited to circular-shaped, oval shaped, rectangular shaped, and square shaped. The perimeter member 22 can be engaged to the body of the stent 10 by at least one connector 44 as shown in FIG. 12.


A long member 24 is engaged to the perimeter member 22. In some embodiments one end of the long member 24 is directly engaged to the perimeter member 22, as shown in FIG. 10A-B. In other embodiments, the long member 24 is not directly engaged to the perimeter member 22, as shown for example in FIG. 11A. As shown in the FIGS. 10A and 10B, the long member 24 has a bend 30. However, it is within the scope of the invention for the long member 24 to be straight, curvilinear, or zig-zag. As used in this application a zig-zag member 42 or connector 44 has at least one bend along the length of the member 42/connector 44. As shown in FIG. 10A, the long member 24 has a first section 26 and a second section 28 engaged by the bend 30. Each section 26, 28 can have any length. Note that the number of bends 30 determines the number of sections that a long member 24 has. Thus, a long member 24 can have one, two three, four, five, six, seven, eight, nine or more sections.


The side branch 20 further comprises a first cell segment 32 and a second cell segment 34, which are engaged to the long member 24. As discussed above, the first and second cell segments 32, 34 define a bi-stable cell 48. In some embodiments, the segments 32, 34 are directly engaged to the long member 24 by a portion of the first cell segment 32, as shown, for example, in FIG. 10B. In other embodiments, the segments 32, 34 indirectly engaged to the long member 24 by at least one short member 42, as shown, for example, in FIG. 10C. The short member 42 can have any configuration, for example, but not limited to, straight, zig-zag, or curvilinear/curved.


As shown in FIG. 10C, the first cell segment 32 is engaged to the long member 24 by two short members 42. It is within the scope of the invention for the first cell segment 32 to be engaged to the long member 24 by any number of short members 42, for example, but not limited to one, two, three, four, five, six or more short members 42. As shown in FIGS. 10B, two short members 42, one at both ends of the segments 32, 34, engage the segments 32, 34 to the long member 24, in addition to the direct engagement of the first cell segment 32 to the long member 24. In this embodiment, the short member 42 should be engaged so as not to affect the ability of the second cell segment 34 to flip from the first state 36 to the second state 38. In some embodiment, the short members 24 are only engaged to any portion of the first cell segment 32.


In at least one embodiment, the second cell segment 34 is engaged to the adjacent long member 24. As shown in FIG. 10A, the second cell segment 34 is engaged to the bend 30 of the adjacent long member 24 by a connector 44. It is within the scope of the invention for the connector 44 to have any length and any configuration, for example, but not limited to straight, zig-zag, or curvilinear/curved. Although the connector 44 is shown being engaged to substantially the middle of the second cell segment 34, the connector 44 can be engaged anywhere along the length of the second cell segment 34.


The side branch 20 also has at least one petal 46. As shown in FIG. 10A, the side branch 20 has twelve petals 46. Thus, it is within the scope of the invention for the side branch 20 to have one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or more petals 46. As shown in FIG. 10A, each petal 46 engages two adjacent long members 24. In some embodiments, the petals 46 are engaged to the ends of the long members 24 and in other embodiments, the petals 46 are engaged to the end regions of the long members 24. As shown in FIGS. 16A-C, at least one portion of the petal 46 can form a cell segment 32, 34 of a bi-stable cell 48. The petal 46 in FIGS. 16A and 16B has one bi-stable cell 48 positioned approximately in the middle section of the petal 46.


It is within the scope of the invention for the petal 46 to have more than one bi-stable cell 48. For example, as shown in FIG. 16C, the petal 46 has two bi-stable cells 48 positioned opposite one another. Note that the first and second segments 32, 34 of the bi-stable cells 48 can have opposite configurations. For example, as shown in FIG. 16C, the first cell segment 32 of one cell 48 forms the proximal side of the bi-stable cell 48 while the first cell segment 32 of the second bi-stable cell 48 forms the distal side of the bi-stable cell 48. In some embodiments, not shown, a portion of the petal 46 forms a portion of a double bi-stable cell geometry.



FIG. 11A is a flat view of an example of another non-limiting configuration for a side branch 20 that has a plurality of bi-stable cells 48a and a plurality of cells 49 with one stable state. FIG. 11B is an enlarged view of a portion of the side branch 20 of FIG. 11A. As discussed above, the side branch 20 in FIG. 11A has bi-stable cells 48a, 48b that are two different sizes/have two different areas A1,A2. However, it is within the scope of the invention for the bi-stable cells 48a, 48b to be the same size/have the same area. Also, as discussed above, the first cell segment 32 of the bi-stable cell 48b can be directly engaged to the perimeter member 22 as shown in FIGS. 11A and 11B or the first cell segment 32 of the bi-stable cell 48b can be indirectly engaged to the perimeter member 22 in a manner similar to the indirect engagement of the bi-stable cell 48 to the long member 24 by the first cell segment 32, shown in FIG. 10C.


In the side branch 20 configuration of FIG. 11A, one end of the long member 24 is engaged to connector 44 instead of to the perimeter member 22, as shown in FIG. 10A. In FIG. 11A all the long members 24 are engaged to connectors 44, but it is within the scope of the invention for at least one of the long member 24 to be engaged to the perimeter member 22. In some embodiments, alternating long members 24 are engaged to the perimeter member 22 and alternating long member 24 are engaged to a connector 44. The connector 44 engages the long member 24 to the second cell segment 34 of bi-stable cell 48b. Although, the connector 44 is engaged to substantially the middle of the second cell segment 34, as discussed above, the connector 44 can be engaged anywhere along the length of the second cell segment 34.



FIG. 12 is a perspective view of the side branch 20 of FIG. 11A and FIGS. 13-15 show the side branch 20 of FIG. 11A being expanded by a balloon which has been omitted in the figures. FIGS. 15A-C show different views, perspective view, side view and end view, respectively, of the expanded side branch 20 of FIG. 11A. In FIG. 12, the bi-stable cells 48 are in the first state 36. In FIGS. 13-14, the bi-stable cells 48 are transitioning to the second state 38. In FIG. 15A, the bi-stable cells 48 are in the second state 38.



FIG. 17 shows a non-limiting example of a side branch 20 configuration comprising a plurality of columns 50 of bi-stable cells 48. It is within the scope of the invention for the side branch 20 to have any number of columns 50 of bi-stable cells 48. In some embodiments, the side branch 20 has at least one column 50 that has both bi-stable cells 48 and cells 49 that are not bi-stable.


The bi-stable cells 48 in columns 50 have the same configuration in FIG. 17. However, in at least one embodiment, the bi-stable cells 48 in a column 50 have different configurations. In some embodiments, the side branch 20 comprises columns 50 which comprise bi-stable cells 48 having a plurality of configurations. In at least one embodiment, adjacent column 50 comprise bi-stable cells 48 having different configurations. Thus, for example, a first column 50 comprises bi-stable cells 48 having a first configuration and a second column 50 comprises bi-stable cells 48 having a second configuration, where the first and second configurations are different.


In some embodiments, the columns 50 are non-tapered. In other embodiments, the columns 50 are tapered, as shown, for example, in FIG. 17. In FIG. 17, the columns 50 are tapered because the bi-stable cells 48 closer to the perimeter member 22 are larger than the bi-stable cells 48 farther away from the perimeter member 22. In at least one embodiment, the side branch 20 comprises a plurality of columns 50 of bi-stable cells 48 where adjacent bi-stable cells 48 in a column 50 are offset from one another, as shown, for example, in FIG. 8E. In these side branch 20 embodiments, the size of the bi-stable cells 48 forming the columns 50 affects the amount of scaffolding provided by the side branch 20. Thus, a side branch 20 with fewer columns 50 with larger sized bi-stable cells 48 provide less scaffolding than a side branch 20 with more columns 50 with smaller sized bi-stable cells 48.


In at least one embodiment, the bi-stable cells 48 of the side branch 20 are arranged so that the side branch 20 extends farther into the side branch vessel when the side branch 20 is in an expanded state. For example, the bi-stable cells 48 are oriented so that the when the bi-stable cell 48 transitions to the second stable state 38, the second cell segment 34 assumes a position that is farther away from the tubular body of the stent. As shown in FIG. 17, adjacent columns 50 of bi-stable cells 48 are engaged by at least one connector 44. The connector 44 can have any length and any configuration, for example, but not limited to straight, zig-zag, curvilinear/curved. Note that if adjacent bi-stable cells 48, for example in a column 50, are engaged by a connector 44 that is configured to increase its longitudinal length upon the expansion of the side branch 20, for example a zig-zag connector 44, the side branch 20 will extend farther into the side branch vessel than if the connector 44 is configured to maintain its longitudinal length upon expansion. Thus, in some embodiments, the amount of vessel coverage by the side branch 20 is optimized by adjusting the orientation of the bi-stable cells 48 and the configuration(s) of the connectors 44 engaging adjacent bi-stable cells 48.


In at least one embodiment, the orientation of the bi-stable cells 48 affects the diameter of the side branch 20. In some embodiments, the side branch 20 comprises at least one ring 52 of bi-stable cells 48. In this embodiment, the bi-stable cells 48 extend about the circumference of the side branch 20. FIG. 18 is a non-limiting example of a side branch 20 with one ring 52 of bi-stable cells 48. The side branch 20 can have a plurality of rings 52 of bi-stable cells 48, with a first ring 52 engaged to the perimeter member 22, a second ring 52 engaged to the first ring 52, a third ring 52 engaged to the second ring 52 and so on. The rings 52 can be engaged to the perimeter member 22 and adjacent rings 52 by a plurality of connectors 44 which can have any length and configuration. Although each bi-stable cell 48 in the ring 52 is engaged to the perimeter member 22 in FIG. 18, it is within the scope of the invention for a portion of the bi-stable cells 48 in the ring 52 not to be engaged to the perimeter member, not shown. In this embodiment, the bi-stable cell 48 would only be engaged to adjacent bi-stable cells 48 in the ring 52.


In some embodiments, bi-stable cells 48 of adjacent rings 52 can be engaged either to a bi-stable cell 48b in the adjacent ring 52 by a connector 44c or to a connector 44a that is engaging adjacent bi-stable cells 48 in the adjacent ring 52, as shown, for example, in FIG. 18. In one embodiment, the connector 44a engaging adjacent bi-stable cells 48 in a ring 52 extends outward when the side branch 20 is expanded thereby extending the connector 44b engaged to the bi-stable cell 48a of the adjacent ring 52 further away from the perimeter member 22. This allows the rings 52 of bi-stable cells 48 to be nested when the side branch 20 is in the unexpanded state and separated from one another when the side branch 20 is in the expanded state so that the bi-stable cells 48 in the side branch 20 have enough space between one another to be in the second state 38. In other embodiments, adjacent rings 52 are engaged by connectors 44. Thus a bridging connector 44e engages a connector 44d in one ring 52 to a connector 44f in the adjacent ring 52, as shown, for example, in FIG. 18.


Adjacent bi-stable cells 48 within a ring 52 can be engaged by a connector 44. As discussed above, the connector 44 can have any configuration and length. In some embodiments, the connector 44 engaging adjacent bi-stable cells 48 in a ring 52 has a first configuration when the side branch 20 is in the unexpanded state and a second configuration when the side branch 20 is in the expanded state. Thus, if the adjacent bi-stable cells 48 are arranged so that the distance between the second segment 34 of one bi-stable cell 48 and the first segment 32 of the adjacent bi-stable cell 48 decreases upon expansion of the side branch 20, the first and second configurations of the connector 44 are different because the configuration of the connector 44 changes to accommodate the decreased distance between adjacent bi-stable cells 48.


Note that the diameter of the side branch 20 in this embodiment depends upon the number of bi-stable cells 48 in a ring 52 and the diameter of each bi-stable cell 48 in the second state 38. In some embodiments, each ring 52 has the same number of bi-stable cells 48. In some embodiments, the side branch 20 has rings 52 with different numbers of bi-stable cells 48. In one embodiment, the side branch 20 is tapered if the number of bi-stable cells 48 in the ring 52 engaged to the perimeter member 22 is greater than the end ring 52 of the side branch 20. In another embodiment, the side branch 20 is not tapered if the number of bi-stable cells 48 in the ring 52 engaged to the perimeter member 22 is less than the end ring 52 of the side branch 20. In some embodiments, the side branch 20 has at least one ring 52 that has bi-stable cells 48 and cells 49 that have only one stable state.


The following numbered statements characterize the embodiments described above:


1. A stent comprising a substantially cylindrical tubular body, the tubular body comprising at least one expandable side branch, the at least one side branch comprising:

    • a first long member;
    • a first cell segment, the first cell segment having a first width, the first cell segment engaged to a portion of the first long member; and
    • a second cell segment, the second cell segment engaged to the first cell segment, the second cell segment having a second width, the second width being less than the first width of the first cell segment, the second cell segment having a first state and a second state, the first and second cell segments defining a first cell, the first cell having a first area when the second cell segment is in the first state, the first cell having a second area when the second cell segment is in the second state, the first area smaller than the second area.


2. The stent of statement 1, the first long member comprising a first section and a second section, the first section at an oblique angle to the second section, the first cell segment engaged to the first section of the first long member


3. The stent of statement 1, the first cell segment directly engaged to the first long member.


4. The stent of statement 3, further comprising at least one first short member, the first cell segment further engaged to the first long member by the at least one first short member.


5. The stent of statement 1, further comprising a first short member, the first cell segment indirectly engaged to the first long member by the first short member.


6. The stent of statement 1, the second cell segment having at least one hinge


7. The stent of statement 1, further comprising a perimeter member, the perimeter member defining a side branch opening, the first long member engaged to the perimeter member.


8. The stent of statement 1, the first cell segment having a first configuration in the first state, the second cell segment having a second configuration in the first state, the first and second configurations being the same.


9. The stent of statement 8, the first cell segment having the first configuration in the second state, the second cell segment having the second configuration in the second state.


10. The stent of statement 8, the first cell segment having the first configuration in the second state, the second cell segment having a third configuration in the second state, the third configuration different than the first configuration.


11. The stent of statement 1, the first cell segment having a first configuration in the first state, the second cell segment having a second configuration in the first state, the first and second configurations being the different.


12. The stent of statement 1, further comprising:

    • a second long member;
    • a first connector, the first connector having a first end and a second end, the first end engaged to the second cell segment and the second end engaged to the second long member.


13. The stent of statement 12, the second long member having a first bend, the second end of the first connector engaged to the first bend of the second long member.


14. The stent of statement 12, further comprising:

    • a first petal, the first petal engaging the first member and the second member.


15. The stent of statement 14, the first long member having a first end, the second long member having a first end, the first petal engaging the first ends of the first and second long members.


16. The stent of statement 14, further comprising:

    • a third cell segment, the third cell segment having a third width; and
    • a fourth cell segment, the fourth cell segment engaged to the third cell segment, the fourth cell segment having a fourth width, the fourth width being less than the third width of the third cell segment, the fourth cell segment having a first state and a second state, the third and fourth cell segments defining a second cell, the second cell having a first area when the fourth cell segment is in the first state, the second cell having a second area when the second cell segment is in the second state, the first area smaller than the second area.


17. The stent of statement 16, the second area of the second cell being less than the second area of the first cell.


18. The stent of statement 16, the third cell segment being directly engaged to the perimeter member.


19. The stent of statement 16, further comprising at least one second short member, the third cell segment being engaged to the perimeter member by at least one second short member.


20. The stent of statement 16, the fourth cell segment being engaged to the first long member.


21. The stent of statement 20, further comprising:

    • a second connector, the second connector engaging the fourth cell segment to the first long member.


The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, magnesium, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy, Platinum Enhanced Radiopaque Stainless Steel (PERSS), and nickel-titanium alloys, for example, Nitinol.


The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon being heated to a transition temperature and having any restraints removed therefrom.


The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.


In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.


In some embodiments the at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto.


A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.


The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.


Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.


This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.

Claims
  • 1. A stent comprising a substantially cylindrical tubular body, the tubular body having a first expandable side branch defining a side branch opening, the first side branch comprising: a plurality of members comprising a plurality of first cell segments, each first cell segment having a first width; anda plurality of second cell segments, each second cell segment having a second width, the first width greater than the second width;a plurality of first bi-stable cells positioned at regular intervals around the first side branch forming a first band of the first side branch, each first bi-stable cell entirely defined by one first cell segment and one second cell segment, each first bi-stable cell having a first stable state with a first stable cell geometry and a second stable state with a second stable cell geometry, wherein in the first stable state the first cell segment is parallel to the second cell segment;a plurality of second bi-stable cells positioned at regular intervals around the first side branch forming a second band of the first side branch, the second band adjacent to the first band, each second bi-stable cell entirely defined by one first cell segment and one second cell segment, each second bi-stable cell having a first stable state with a first stable cell geometry and a second stable state with a second stable cell geometry, wherein in the first stable state the first cell segment is parallel to the second cell segment;a plurality of long members, each long member having a first section, a second section, and a bend extending from the first section and the second section, a portion of the second section of each long member defining a portion of the side branch opening, each first bi-stable cell connected to the first section of a long member, and each second bi-stable cell connected to the first section of a long member.
  • 2. The stent of claim 1, further comprising a second cell having only one stable cell geometry.
  • 3. The stent of claim 2, the second cell defined in part by a portion of the second cell segment.
  • 4. The stent of claim 3, the second cell further defined in part by at least one portion of the first cell segment
  • 5. The stent of claim 1, the plurality of first cell segments comprising a primary first cell segment, the plurality of second cell segments comprising a primary second cell segment and a secondary second cell segment, the plurality of first bi-stable cells comprising a primary first bi-stable cell, the primary first bi-stable cell being entirely defined by the primary first cell segment and the primary second cell segment; anda secondary first bi-stable cell, the secondary first bi-stable cell being entirely defined by the primary first cell segment and the secondary second cell segment.
  • 6. The stent of claim 5, the at least two different stable cell geometries of the primary first bi-stable cell comprising a first stable cell geometry and a second stable cell geometry, the at least two different stable cell geometries of the secondary first bi-stable cell comprising a third stable cell geometry and a fourth stable cell geometry, the first stable cell geometry and the third stable cell geometry being the same stable cell geometry.
  • 7. The stent of claim 1, the at least two different stable cell geometries comprising a first stable cell geometry, an intermediate cell geometry and a second cell geometry, the first stable cell geometry being C-shaped, the intermediate cell geometry being irregular-shaped, the second cell geometry being polygonal.
  • 8. The stent of claim 1, the second cell segment being in a different stable position in each of the at least two different stable cell geometries, the different stable position of the second cell segment in each of the at least two stable cell geometries being obtained when only a position of the second cell segment changes relative to a stable position of the first cell segment.
  • 9. The stent of claim 1, wherein first stable cell geometry is a curvilinear configuration.
  • 10. The stent of claim 1, the first side branch defining a side branch opening and further comprising a plurality of long members, each first bi-stable cell being engaged to a portion of a long member, a first end region of each long member defining a portion of the side branch opening.
  • 11. The stent of claim 1, each first bi-stable cell having a first size, each second bi-stable cell having a second size less than the first size, each first bi-stable cell being connected to one second bi-stable cell and two other first bi-stable cells.
  • 12. The stent of claim 1, the first side branch further comprising a plurality of petals, each petal connected to and extending between two long members, the plurality of petals forming a third band of the first side branch, the first band being between the second and third bands, the third band forming a distal end region of the first side branch and the second band forming a proximal end region of the first side branch.
  • 13. The stent of claim 1, wherein each first bi-stable cell changes from one stable state to another stable state only when a force applied exceeds the equilibrium position, wherein an external force is required to maintain the first bi-stable cell in a position between the first and second stable states.
  • 14. A stent comprising a substantially cylindrical tubular body, the tubular body having a first expandable side branch, the first side branch comprising: a plurality of members comprising a plurality of first cell segments, each first cell segment having a first width; anda plurality of second cell segments, each second cell segment having a second width, the first width greater than the second width;a plurality of first bi-stable cells positioned at regular intervals around the first side branch forming a first band of the first side branch, each first bi-stable cell entirely defined by one first cell segment and one second cell segment, each first bi-stable cell having a first stable state with a first stable cell geometry and a second stable state with a second stable cell geometry, wherein in the first stable state the first cell segment is parallel to the second cell segment;a plurality of second bi-stable cells positioned at regular intervals around the first side branch forming a second band of the first side branch, the second band adjacent to the first band, each second bi-stable cell entirely defined by one first cell segment and one second cell segment, each second bi-stable cell having a first stable state with a first stable cell geometry and a second stable state with a second stable cell geometry, wherein in the first stable state the first cell segment is parallel to the second cell segment;a plurality of petals, each petal connected to and extending between two long members, the plurality of petals forming a third band of the first side branch, the first band being between the second and third bands, the third band forming a distal end region of the first side branch and the second band forming a proximal end region of the first side branch.
  • 15. The stent of claim 14, each first bi-stable cell having a first size, each second bi-stable cell having a second size less than the first size, each first bi-stable cell being connected to one second bi-stable cell and two other first bi-stable cells.
  • 16. The stent of claim 14, wherein each first bi-stable cell changes from one stable state to another stable state only when a force applied exceeds the equilibrium position, wherein an external force is required to maintain the first bi-stable cell in a position between the first and second stable states.
US Referenced Citations (375)
Number Name Date Kind
4309994 Grunwald Jan 1982 A
4769005 Ginsburg et al. Sep 1988 A
4774949 Fogarty Oct 1988 A
4896670 Crittenden Jan 1990 A
4905667 Foerster et al. Mar 1990 A
4906244 Pinchuk et al. Mar 1990 A
4935190 Tennerstedt Jun 1990 A
4994071 MacGregor Feb 1991 A
5037392 Hillstead Aug 1991 A
5053007 Euteneuer Oct 1991 A
5087246 Smith Feb 1992 A
5112900 Buddenhagen et al. May 1992 A
5147302 Euteneuer et al. Sep 1992 A
5163989 Campbell et al. Nov 1992 A
5209799 Vigil May 1993 A
5226887 Farr et al. Jul 1993 A
5306246 Sahatjian et al. Apr 1994 A
5318587 Davey Jun 1994 A
5342307 Euteneuer et al. Aug 1994 A
5342387 Summers Aug 1994 A
5348538 Wang et al. Sep 1994 A
5350361 Tsukashima et al. Sep 1994 A
5358475 Mares et al. Oct 1994 A
5387235 Chuter Feb 1995 A
5403340 Wang et al. Apr 1995 A
5447497 Sogard et al. Sep 1995 A
5456666 Campbell et al. Oct 1995 A
5456712 Maginot Oct 1995 A
5458572 Campbell et al. Oct 1995 A
5476471 Shifrin et al. Dec 1995 A
5478319 Campbell et al. Dec 1995 A
5487730 Marcadis et al. Jan 1996 A
5523092 Hanson et al. Jun 1996 A
5549552 Peters et al. Aug 1996 A
5550180 Elsik et al. Aug 1996 A
5556383 Wang et al. Sep 1996 A
5591228 Edoga Jan 1997 A
5607444 Lam Mar 1997 A
5609605 Marshall et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5613980 Chauhan Mar 1997 A
5617878 Taheri Apr 1997 A
5632762 Myler May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5669924 Shaknovich Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5676697 McDonald Oct 1997 A
5683450 Goicoechea et al. Nov 1997 A
5697971 Fischell et al. Dec 1997 A
5707348 Krogh Jan 1998 A
5709713 Evans et al. Jan 1998 A
5718684 Gupta Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5746745 Abele et al. May 1998 A
5749825 Fischell et al. May 1998 A
5749890 Shaknovich May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755771 Penn et al. May 1998 A
5755773 Evans et al. May 1998 A
5755778 Kleshinski May 1998 A
5782906 Marshall et al. Jul 1998 A
5800520 Fogarty et al. Sep 1998 A
5810767 Klein Sep 1998 A
5824036 Lauterjung Oct 1998 A
5824040 Cox et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5830182 Wang et al. Nov 1998 A
5833657 Reinhardt et al. Nov 1998 A
5843172 Yan Dec 1998 A
5851464 Davila et al. Dec 1998 A
5868777 Lam Feb 1999 A
5882334 Sepetka et al. Mar 1999 A
5891108 Leone et al. Apr 1999 A
5893887 Jayaraman Apr 1999 A
5906640 Penn et al. May 1999 A
5922020 Klein et al. Jul 1999 A
5922021 Jang Jul 1999 A
5951941 Wang et al. Sep 1999 A
5961548 Shmulewitz Oct 1999 A
5972017 Berg et al. Oct 1999 A
5972027 Johnson Oct 1999 A
6013054 Jiun Yan Jan 2000 A
6013055 Bampos et al. Jan 2000 A
6013091 Ley et al. Jan 2000 A
6017324 Tu et al. Jan 2000 A
6017363 Hojeibane Jan 2000 A
6030414 Taheri Feb 2000 A
6033380 Butaric et al. Mar 2000 A
6033433 Ehr et al. Mar 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6048361 Von Oepen Apr 2000 A
6056775 Borghi et al. May 2000 A
6059824 Taheri May 2000 A
6068655 Seguin et al. May 2000 A
6071285 Lashinski et al. Jun 2000 A
6071305 Brown et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6093203 Uflacker Jul 2000 A
6096070 Ragheb et al. Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6113579 Eidenschink et al. Sep 2000 A
6117117 Mauch Sep 2000 A
6117156 Richter et al. Sep 2000 A
6123721 Jang Sep 2000 A
6126652 McLeod et al. Oct 2000 A
6129738 Lashinski et al. Oct 2000 A
6129754 Kanesaka et al. Oct 2000 A
6135982 Campbell Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6143002 Vietmeier Nov 2000 A
6146356 Wang et al. Nov 2000 A
6159238 Killion et al. Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6168621 Vrba Jan 2001 B1
6171278 Wang et al. Jan 2001 B1
6183509 Dibie Feb 2001 B1
6190404 Palmaz et al. Feb 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6206915 Fagan et al. Mar 2001 B1
6206916 Furst Mar 2001 B1
6210380 Mauch Apr 2001 B1
6210429 Vardi et al. Apr 2001 B1
6210433 Larre Apr 2001 B1
6210436 Weadock Apr 2001 B1
6231598 Berry et al. May 2001 B1
6240616 Yan Jun 2001 B1
6241762 Shanley Jun 2001 B1
6253443 Johnson Jul 2001 B1
6254593 Wilson Jul 2001 B1
6254632 Wu et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6258121 Yang et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6261320 Tam et al. Jul 2001 B1
6264662 Lauterjung Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6273908 Ndonda-Lay Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6280413 Clark et al. Aug 2001 B1
6287628 Hossainy et al. Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293967 Shanley Sep 2001 B1
6293968 Taheri Sep 2001 B1
6325826 Vardi et al. Dec 2001 B1
6328925 Wang et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6334870 Ehr et al. Jan 2002 B1
6346089 Dibie Feb 2002 B1
6348065 Brown et al. Feb 2002 B1
6355060 Lenker et al. Mar 2002 B1
6358552 Mandralis et al. Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6361555 Wilson Mar 2002 B1
6379381 Hossainy et al. Apr 2002 B1
6383213 Wilson et al. May 2002 B2
6395018 Castaneda May 2002 B1
6395326 Castro et al. May 2002 B1
6406457 Wang et al. Jun 2002 B1
6423091 Hojeibane Jul 2002 B1
6436104 Hojeibane Aug 2002 B2
6436134 Richter et al. Aug 2002 B2
6478816 Kveen et al. Nov 2002 B1
6488702 Besselink Dec 2002 B1
6491666 Santini, Jr. et al. Dec 2002 B1
6506437 Harish et al. Jan 2003 B1
6508836 Wilson et al. Jan 2003 B2
6517558 Gittings et al. Feb 2003 B2
6520988 Colombo et al. Feb 2003 B1
6527762 Santini, Jr. et al. Mar 2003 B1
6527799 Shanley Mar 2003 B2
6537256 Santini, Jr. et al. Mar 2003 B2
6540779 Richter et al. Apr 2003 B2
6551351 Smith et al. Apr 2003 B2
6551838 Santini, Jr. et al. Apr 2003 B2
6558422 Baker et al. May 2003 B1
6562065 Shanley May 2003 B1
6579309 Loos et al. Jun 2003 B1
6579312 Wilson et al. Jun 2003 B2
6582394 Reiss et al. Jun 2003 B1
6596020 Vardi et al. Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6638302 Curcio et al. Oct 2003 B1
6645242 Quinn Nov 2003 B1
6656162 Santini, Jr. et al. Dec 2003 B2
6669683 Santini, Jr. et al. Dec 2003 B2
6689156 Davidson et al. Feb 2004 B1
6692483 Vardi et al. Feb 2004 B2
6695877 Brucker et al. Feb 2004 B2
6706062 Vardi et al. Mar 2004 B2
6709379 Brandau et al. Mar 2004 B1
6713119 Hossainy et al. Mar 2004 B2
6730064 Ragheb et al. May 2004 B2
6749628 Callol et al. Jun 2004 B1
6758859 Dang et al. Jul 2004 B1
6764507 Shanley et al. Jul 2004 B2
6773429 Sheppard, Jr. et al. Aug 2004 B2
6776793 Brown et al. Aug 2004 B2
6783543 Jang Aug 2004 B2
6790228 Hossainy et al. Sep 2004 B2
6811566 Penn et al. Nov 2004 B1
6827250 Uhland et al. Dec 2004 B2
6835203 Vardi et al. Dec 2004 B1
6858038 Heuser Feb 2005 B2
6884258 Vardi et al. Apr 2005 B2
6896699 Wilson et al. May 2005 B2
6904658 Hines Jun 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6946092 Bertolino et al. Sep 2005 B1
6955687 Richter et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6962602 Vardi et al. Nov 2005 B2
6989071 Kocur et al. Jan 2006 B2
7018400 Lashinski et al. Mar 2006 B2
7022131 Derowe et al. Apr 2006 B1
7041130 Santini, Jr. et al. May 2006 B2
7052488 Uhland May 2006 B2
7056323 Mareiro et al. Jun 2006 B2
7056338 Shanley et al. Jun 2006 B2
7060084 Loshakove et al. Jun 2006 B1
7060091 Killion et al. Jun 2006 B2
7070616 Majercak et al. Jul 2006 B2
7160321 Shanley et al. Jan 2007 B2
7169175 Cottone, Jr. et al. Jan 2007 B2
7169179 Shanley et al. Jan 2007 B2
7179288 Shanley Feb 2007 B2
7179289 Shanley Feb 2007 B2
7208010 Shanley et al. Apr 2007 B2
7208011 Shanley et al. Apr 2007 B2
7220275 Davidson et al. May 2007 B2
7235097 Calisse et al. Jun 2007 B2
7722658 Richter et al. May 2010 B2
7959668 Yadin Jun 2011 B2
20010003161 Vardi et al. Jun 2001 A1
20010004706 Hojeibane Jun 2001 A1
20010004707 Dereume et al. Jun 2001 A1
20010012927 Mauch Aug 2001 A1
20010016766 Vardi et al. Aug 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010016768 Wilson et al. Aug 2001 A1
20010025195 Shaolian et al. Sep 2001 A1
20010027291 Shanley Oct 2001 A1
20010027338 Greenberg Oct 2001 A1
20010029396 Wilson et al. Oct 2001 A1
20010037116 Wilson et al. Nov 2001 A1
20010037138 Wilson et al. Nov 2001 A1
20010039448 Dibie Nov 2001 A1
20010049552 Richter et al. Dec 2001 A1
20010056297 Hojeibane Dec 2001 A1
20020013618 Marotta et al. Jan 2002 A1
20020013619 Shanley Jan 2002 A1
20020022874 Wilson Feb 2002 A1
20020026232 Marotta et al. Feb 2002 A1
20020035392 Wilson Mar 2002 A1
20020038146 Harry Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052648 McGuckin, Jr. et al. May 2002 A1
20020072790 McGuckin, Jr. et al. Jun 2002 A1
20020095208 Gregorich et al. Jul 2002 A1
20020107562 Hart Aug 2002 A1
20020111675 Wilson Aug 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020156517 Perouse Oct 2002 A1
20020163104 Motsenbocker et al. Nov 2002 A1
20020165604 Shanley Nov 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020193872 Trout, III et al. Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030009209 Hojeibane Jan 2003 A1
20030028233 Vardi et al. Feb 2003 A1
20030050688 Fischell et al. Mar 2003 A1
20030055378 Wang et al. Mar 2003 A1
20030055483 Gumm Mar 2003 A1
20030074047 Richter Apr 2003 A1
20030083687 Pallazza May 2003 A1
20030093109 Mauch May 2003 A1
20030097169 Brucker May 2003 A1
20030105511 Welsh et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030163157 McMorrow et al. Aug 2003 A1
20030167085 Shanley Sep 2003 A1
20030181923 Vardi Sep 2003 A1
20030195606 Davidson et al. Oct 2003 A1
20030199970 Shanley Oct 2003 A1
20040006381 Sequin et al. Jan 2004 A1
20040015227 Vardi et al. Jan 2004 A1
20040044396 Clerc et al. Mar 2004 A1
20040059406 Cully et al. Mar 2004 A1
20040068161 Couvillon, Jr. Apr 2004 A1
20040073294 Diaz et al. Apr 2004 A1
20040088007 Eidenschink May 2004 A1
20040093071 Jang May 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040122505 Shanley Jun 2004 A1
20040122506 Shanley et al. Jun 2004 A1
20040127976 Diaz Jul 2004 A1
20040127977 Shanley Jul 2004 A1
20040133268 Davidson et al. Jul 2004 A1
20040138732 Suhr et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040142014 Livack et al. Jul 2004 A1
20040143321 Livack et al. Jul 2004 A1
20040143322 Livack et al. Jul 2004 A1
20040148006 Davidson et al. Jul 2004 A1
20040148012 Jang Jul 2004 A9
20040172121 Eidenschink et al. Sep 2004 A1
20040186560 Alt Sep 2004 A1
20040202692 Shanley et al. Oct 2004 A1
20040204750 Dinh Oct 2004 A1
20040215227 McMorrow et al. Oct 2004 A1
20040220661 Shanley et al. Nov 2004 A1
20040225345 Fischell et al. Nov 2004 A1
20040236408 Shanley Nov 2004 A1
20040249449 Shanley et al. Dec 2004 A1
20040267352 Davidson et al. Dec 2004 A1
20050004656 Das Jan 2005 A1
20050010278 Vardi et al. Jan 2005 A1
20050015108 Williams et al. Jan 2005 A1
20050015135 Shanley Jan 2005 A1
20050043816 Datta et al. Feb 2005 A1
20050060027 Khenansho et al. Mar 2005 A1
20050096726 Sequin et al. May 2005 A1
20050102017 Mattison May 2005 A1
20050102021 Osborne May 2005 A1
20050102023 Yadin et al. May 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050125076 Ginn Jun 2005 A1
20050131526 Wong Jun 2005 A1
20050149161 Eidenschink et al. Jul 2005 A1
20050154442 Eidenschink et al. Jul 2005 A1
20050154444 Quadri Jul 2005 A1
20050183259 Eidenschink et al. Aug 2005 A1
20050187602 Eidenschink Aug 2005 A1
20050187611 Ding et al. Aug 2005 A1
20050192657 Colen et al. Sep 2005 A1
20050209673 Shaked Sep 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050228483 Kaplan et al. Oct 2005 A1
20050273149 Tran et al. Dec 2005 A1
20060015134 Trinidad Jan 2006 A1
20060034884 Stenzel Feb 2006 A1
20060036315 Yadin et al. Feb 2006 A1
20060041303 Israel Feb 2006 A1
20060045901 Weber Mar 2006 A1
20060079956 Eigler et al. Apr 2006 A1
20060088654 Ding et al. Apr 2006 A1
20060093643 Stenzel May 2006 A1
20060100686 Bolduc May 2006 A1
20060122698 Spencer et al. Jun 2006 A1
20060155360 Calisse et al. Jul 2006 A1
20060173528 Feld et al. Aug 2006 A1
20060206188 Weber et al. Sep 2006 A1
20060217795 Besselink et al. Sep 2006 A1
20060287712 Eidenschink Dec 2006 A1
20070005126 Tischler Jan 2007 A1
20070050016 Gregorich et al. Mar 2007 A1
20070073376 Krolik et al. Mar 2007 A1
20070073384 Brown et al. Mar 2007 A1
20070100434 Gregorich et al. May 2007 A1
20070135904 Eidenschink et al. Jun 2007 A1
20070173787 Huang et al. Jul 2007 A1
20070173923 Savage et al. Jul 2007 A1
20070208408 Weber et al. Sep 2007 A1
Foreign Referenced Citations (127)
Number Date Country
2220864 Jul 1999 CA
9014845 Feb 1991 DE
29701758 Mar 1997 DE
29701883 May 1997 DE
19921788 Nov 2000 DE
0479730 Oct 1991 EP
0565796 Oct 1993 EP
0751752 Jan 1997 EP
0783873 Jul 1997 EP
0804907 Nov 1997 EP
0479557 Jul 1998 EP
0876805 Nov 1998 EP
0880949 Dec 1998 EP
0891751 Jan 1999 EP
0895759 Feb 1999 EP
0904745 Mar 1999 EP
0937442 Aug 1999 EP
0950386 Oct 1999 EP
0347023 Dec 1999 EP
1031328 Aug 2000 EP
1031329 Aug 2000 EP
0883384 Dec 2000 EP
0862392 Aug 2001 EP
0808140 Dec 2001 EP
0884028 Feb 2002 EP
1190685 Mar 2002 EP
0897700 Jul 2002 EP
0684022 Feb 2004 EP
1157674 Jul 2005 EP
1031330 Nov 2005 EP
1070513 Jun 2006 EP
2678508 Jan 1993 FR
2740346 Oct 1995 FR
2756173 Nov 1996 FR
2337002 May 1998 GB
8806026 Aug 1988 WO
9423787 Oct 1994 WO
9521592 Aug 1995 WO
9629955 Oct 1996 WO
9634580 Nov 1996 WO
9641592 Dec 1996 WO
9707752 Mar 1997 WO
9715346 May 1997 WO
9716217 May 1997 WO
9726936 Jul 1997 WO
9741803 Nov 1997 WO
9745073 Dec 1997 WO
9746174 Dec 1997 WO
9819628 May 1998 WO
9823228 Jun 1998 WO
9832412 Jul 1998 WO
9836709 Aug 1998 WO
9836784 Aug 1998 WO
9837833 Sep 1998 WO
9847447 Oct 1998 WO
9848879 Nov 1998 WO
9903426 Jan 1999 WO
9904726 Feb 1999 WO
9915103 Apr 1999 WO
9915108 Apr 1999 WO
9915109 Apr 1999 WO
9923977 May 1999 WO
9924104 May 1999 WO
9929262 Jun 1999 WO
9934749 Jul 1999 WO
9936002 Jul 1999 WO
9936015 Jul 1999 WO
9944539 Sep 1999 WO
9956661 Nov 1999 WO
9965419 Dec 1999 WO
0007523 Feb 2000 WO
0010489 Mar 2000 WO
0016719 Mar 2000 WO
0027307 May 2000 WO
0027463 May 2000 WO
0028922 May 2000 WO
0145594 Jun 2000 WO
0044307 Aug 2000 WO
0044309 Aug 2000 WO
0047134 Aug 2000 WO
0048531 Aug 2000 WO
0049951 Aug 2000 WO
0051523 Sep 2000 WO
0057813 Oct 2000 WO
0067673 Nov 2000 WO
0071054 Nov 2000 WO
0071055 Nov 2000 WO
0074595 Dec 2000 WO
0117577 Mar 2001 WO
0121095 Mar 2001 WO
0121109 Mar 2001 WO
0121244 Mar 2001 WO
0126584 Apr 2001 WO
0135715 May 2001 WO
0135863 May 2001 WO
0139697 Jun 2001 WO
0139699 Jun 2001 WO
0141677 Jun 2001 WO
0143665 Jun 2001 WO
0143809 Jun 2001 WO
0145785 Jun 2001 WO
0149342 Jul 2001 WO
0154621 Aug 2001 WO
0154622 Aug 2001 WO
0158385 Aug 2001 WO
0160284 Aug 2001 WO
0166036 Sep 2001 WO
0170294 Sep 2001 WO
0170299 Sep 2001 WO
0174273 Oct 2001 WO
0191918 Dec 2001 WO
0193781 Dec 2001 WO
0200138 Jan 2002 WO
02053066 Jul 2002 WO
02068012 Sep 2002 WO
03007842 Jan 2003 WO
03055414 Jul 2003 WO
03063924 Aug 2003 WO
2004026174 Apr 2004 WO
2004026180 Apr 2004 WO
2005009295 Feb 2005 WO
2005014077 Feb 2005 WO
2005041810 May 2005 WO
2005122959 Dec 2005 WO
2006028925 Mar 2006 WO
2006074476 Jul 2006 WO
2006127127 Nov 2006 WO
Related Publications (1)
Number Date Country
20090163993 A1 Jun 2009 US